1.
Introduction Prostate cancer (PCa) is the most common noncutaneous malignancy and the second leading cause of cancer deaths in men. Localized PCa is treated with surgery, radiation, or surveillance, whereas androgen-deprivation therapy (castration) is the standard of care for advanced PCa [1, 2] . Typically, most patients respond to castration as demonstrated by falling prostate-specific antigen (PSA) and quick relief of symptoms [3] . Ultimately, the disease progresses (rising PSA and/or growth of metastases) to a state called castrationresistant prostate cancer (CRPC) [4] . At this stage, alternative treatments available include novel drugs such as abiraterone and enzalutamide, radium-223 (a radiopharmaceutical), and cytotoxic drugs such as docetaxel and cabazitaxel [5] [6] [7] [8] [9] [10] [11] . However, eventually the cancer cells become resistant to hormonal and radiopharmaceutical treatments and the currently available cytotoxic drugs.
The prostate gland consists of glandular epithelium in which five cell types have been identified: basal, transitamplifying (TA), luminal, neuroendocrine, and stem cells [12] . Basal cells are androgen independent and can be characterized by their expression of cytokeratins (CK)-5 and CK14. In contrast, luminal epithelial cells are androgen dependent and can be identified by CK18, androgen receptor (AR), and PSA expression. The TA cells are thought to migrate from the basal to the luminal layer as they differentiate and express a combination of markers common to both cell types [12] [13] [14] . It has been suggested that PCa may arise from the AR-negative, androgenindependent basal stem cells, which are able to survive during androgen deprivation therapy [12] . Furthermore, cells expressing low amounts of AR and PSA within the prostate have been suggested to exhibit long-term tumorpropagating capacity and are not vulnerable to stress caused by the androgen deprivation [15] .
Establishment and maintenance of long-term ex vivo cultures directly from patient-derived prostate tumor tissue samples has been very challenging, but this is starting to change due to recent breakthroughs in two dimensional (2D) and 3D cell culture technologies [16] [17] [18] . These new primary culture technologies consist of either conditionally reprogrammed cells (CRCs) cocultured as monolayers (in 2D) with feeder cells (irradiated-3T3 mouse fibroblasts) in the presence of a Rho-associated protein kinase inhibitor (ROCKi) or of patient-derived spheroids or organoids (in 3D). Importantly, these models are not established through xenografting or exogenous gene transfer and they could become critically important in understanding the disease and identifying new therapeutic agents for PCa.
Here, we generated patient-derived CRCs of PCa from castration-naïve PCa to CRPC as well as from benign tissues as controls. We characterized these CRCs with genomic, transcriptomic, and protein expression profiling and compared them with the parental tissues from which they were isolated. We then performed comprehensive drug sensitivity testing with 306 oncology drugs to identify clinical and emerging oncology drugs that could be effective for PCa-derived CRCs [19, 20] .
2.
Materials and methods
Tissue processing and establishment of CRCs
Prostate tissue was collected from seven patients undergoing prostatectomy, transurethral resection of the prostate, or ultrasound-guided needle biopsy at Helsinki University Hospital. Samples were obtained from patients participating with informed consent in the Urological Biobank Initiative (Helsinki Urological Biobank; HUB). With radical prostatectomy patient samples, a cylinder shaped core of prostate tissue (8-mm diameter) was cored out of the peripheral dorsal region of the prostate and tissue was processed as illustrated in Figure 1 . Primary cells for the establishment of CRCs were isolated from the middle section of the core. The ratio of benign and malignant cells in the parental tissue was evaluated from tissue sections adjacent to the section used for CRC establishment using hematoxylin and eosin staining (Supplementary Table 1 ). The inclusion criteria for the patient samples included the ratio of benign and malignant cells in the tissue; therefore, only tissues without cancer cells were used for benign CRC establishment and tissues with less than 15% of contaminating benign cells were used for cancer CRC establishment. The methodology is described in more detail in the supplementary material.
Copy number aberration analysis
Genomic DNA was extracted from parental tissues, CRCs, and germline control blood cells using the DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany). The methodology and analysis pipeline are described in the supplementary material. 
Drug sensitivity testing
The CRCs established from the patient samples were cultured for 3-7 wk and used for drug testing with 306 clinical (Food and Drug Administration and/or European Medicines Agency-approved) and emerging oncology drugs as described in Pemovska et al [19] . Briefly, cells were exposed to drugs in five different concentrations for 72 h. Supplementary Fig. 3 ).
The comparison of the drug sensitivity score (DSS) between the replicate screens showed strong correlation (R 2 > 0.90, p < 0.0001), and thus to maintain an optimal proliferative state of the CRCs (Fig. 1D ). Y-27632 was present in all the subsequent tests.
Statistical analysis
The dose-response percent inhibition data points were fitted into a fourparameter logistic model to calculate IC50, slope, top, and lower asymptotes. These parameters were used to quantify the drug response, (selective DSS) as previously described [20] . Pearson correlation coefficient was used to assess the significance of correlations displayed in the XY plots across drug sensitivity and GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA) was used to generate these plots as well as the combined dose-response curve fits illustrated in Supplementary Clustering of the drug sensitivity profiles across the samples was done with unsupervised hierarchical clustering based on the Ward-linkage method and Spearman's rank as the distance metric.
Results

Prostate tissue processing and establishment of the CRC cultures
For this study, we selected seven patients whose disease ranged from benign to early prostate cancer and CRPC (HUB.1-7; Table 1 ). Based on the histological evaluation, altogether seven tumor and two benign samples were used for the establishment of CRCs (Table 1 , Fig. 1A and 1B, Supplementary Table 1 ). The CRCs were generated through coculturing of freshly isolated patient cells and feeder cells in culture medium supplemented with ROCKi [16] . In this system patient-derived CRCs grow in colonies typical of epithelial cells (Fig. 1C ). The optimal growth conditions for the CRCs were tested in live phase contrast imaging in four different conditions: (1) with both feeder cells and ROCKi, (2) with feeder cells only, (3) with ROCKi only, and (4) without feeder cells and ROCKi. The results show that both feeder cells and ROCKi were necessary for the optimal cell growth ( Fig. 1D ). Seven out of nine (78%) attempts to start CRC cultures were successful. The CRCs were characterized with genomic, transcriptomic, and protein expression profiling, and compared with the parental tissue from which the benign and cancer cells were isolated (Supplementary Table 2 ).
Molecular characteristics of the CRCs
To define and quantify the phenotypic variation in the CRCs, we performed IF labeling of the cells coupled with supervised machine learning image analysis using five classifiers: (1) cell nuclei, (2) basal cells (CK5/p63 positive), (3) luminal cells (CK18 positive), and (4) TA cells (CK5/p63 and CK18 positive), as well as (5) other types. We observed basal cell markers p63/CK5 and luminal cell marker CK18 being expressed either alone or simultaneously (TA phenotype) in all CRCs ( Fig. 2A and 2B ). Five out of seven (71%) CRCs were dominated by the TA phenotype whereas in two CRCs (HUB.1 and HUB.5), the basal phenotype was more prominent. Additionally, HUB.3.CC displayed a strong luminal population (45%). We confirmed the expression of these cell type-specific markers using western blotting and IHC of formalin-fixed, paraffin-embedded samples from the corresponding tissue and CRCs (Fig. 2C and 2D , Supplementary Fig. 1 ). All the CRCs were found to be AR and PSA negative in contrast to their parental tissue ( Fig. 2C and 2D , Supplementary Fig. 1 ), which was also confirmed by RNAsequencing and quantitative polymerase chain reaction (data not shown). We were able to restore AR expression in HUB.1 CRCs when grown in 3D spheroid culture ( Fig. 2E) , whereas the CRPC-derived HUB.5 CRCs were not able to grow as spheroids (data not shown).
Genomic analysis was performed to identify cancerspecific copy number aberrations (CNAs) in the CRCs and compare these with the CNAs found in the parental tissue. Most of the CRCs had no shared CNAs with the matching parental tissue, suggesting that they represented benign cells ( Supplementary Fig. 2A ). In contrast, HUB.5 CRCs shared the same cancer-specific deletions at chromosomes 1p and 16p with their parental tumor tissue ( Fig. 2F , Supplementary Fig. 2B) . A full list of HUB.5 CRC-specific somatic mutations is provided in Supplementary  Table 3 . Thus, the HUB.5 CRC model appears to be a bona fide PCa CRC model established in this study.
3.3.
Comprehensive oncology drug testing in the CRPC-derived
HUB.5 CRCs
To identify vulnerabilities of HUB.5 CRCs towards oncology drugs we performed drug testing using 306 oncology drugs in five different concentrations and measured cell viability after 72 h of drug exposure [19, 20] ( Supplementary  Table 4 ). To obtain a HUB.5 cancer-selective sensitivity profile, we used two sets of controls, the first set with the mean of two CRC models derived from benign prostate tissue (HUB.2.BC and HUB.3.BC) and the second set with the mean of all other CRCs established in this study, except for HUB.5. The results from both sets of controls showed cancer-specific DSS for HUB.5 for several drugs that included navitoclax, bexarotene, tretinoin, oxaliplatin, and mepacrine ( Fig. 3A and 3B , Supplementary Table 4 ). Unsupervised hierarchical clustering was applied to compare the overall drug response profile of the HUB.5 CRCs with all the other CRCs, as well as to the commonly used PCa cell lines LNCaP, LAPC4, PC3, and VCaP (Fig. 3C) . Altogether, 46 drugs were more effective in HUB.5 CRCs than the mean of the controls and six drugs showed lower efficacy ( Supplementary Table 4B ). HUB.5 CRCs clustered together with the PCa cell lines VCaP and LNCaP, whereas the other CRCs formed a distinct cluster. Of the drugs highlighted, oxaliplatin and docetaxel as well as mepacrine (an antimalaria drug) have been tested in clinical trials for CRPC (clinicaltrials.gov; NCT00260611, NCT01487720, NCT00417274). Gemcitabine also showed high efficacy in HUB.5 CRCs (cluster 3) and the combination of gemcitabine with oxaliplatin has been suggested as a second-line treatment option for metastatic CRPC after failure of docetaxel [21] . Interestingly, docetaxel and paclitaxel are found in cluster 4 along with navitoclax, which was the most effective targeted drug and the most specific for HUB.5 CRCs (Fig. 3A and 3B, Supplementary Table 4 ). Navitoclax in combination with abiraterone is currently undergoing phase II trials for metastatic CRPC (NCT01828476).
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3.4.
Navitoclax induces apoptosis in CRPC-derived HUB.5 CRCs RNA sequencing data indicated elevated expression of Bcl-2 family members Bcl-xL and Mcl-1 in both HUB.5 tumor tissue and CRCs (Fig. 4A) . These finding were validated using quantitative polymerase chain reaction and IHC for Bcl-xL and Mcl-1 (Fig. 4B and 4C) . To validate the navitoclax sensitivity of HUB.5 CRCs, we quantified the apoptotic cells by the expression of cleaved Caspase-3 under navitoclax exposure using IF labeling and supervised machine learning image analysis. These results show an increase in cleaved Caspase-3-positive cells after 24-72 h of navitoclax treatment compared with mock treated cells ( Fig. 4D and  4E) . Similarly, western blotting analysis validated the apoptotic response of navitoclax showing cleavage of caspase-3 only in HUB.5 CRCs (Fig. 4F) , and not in two other CRCs (HUB.1 and HUB.3.CC) which were also resistant to navitoclax in the primary testing ( Supplementary Fig. 4A  and 4B ). Together, these results show that navitoclax, initially identified through drug testing, is effective in inducing apoptosis in the CRPC-derived HUB.5 CRCs. HUB.5 CRCs' sensitivity to navitoclax is consistent with the protein expression profile showing increased expression of Bcl-2 family members Bcl-xL and Mcl-1 (Fig. 4C ).
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Discussion
We had almost 80% success in establishing ex vivo CRC cultures from prostate tissues, including one CRC culture with a clonal relationship to the original tumor tissue was established from a patient with CRPC (HUB.5). The patient with a more clinically aggressive disease (HUB.5) had a relatively homogenous cancer content with no benign cells present in the parental tissue specimen. This sample gave rise to CRCs presenting shared CNAs with the parental tissue, while most other PCa samples gave rise to genomically normal, likely benign cell cultures. The majority of the CRCs were identified as TA, which is in agreement with the presumed cell type that acts as a prostate progenitor [22] . TA cells are androgen-independent and do not express AR or PSA, but this phenotype is transitory and the cells differentiate to express luminal markers in appropriate growth conditions. AR and PSA negative cancer cells have been suggested to exhibit long-term tumorpropagating capacity, and they are refractory to androgen deprivation and consequently evade apoptosis during treatment [15] . Moreover, these types of cells have been suggested to repopulate the tumors after antiandrogen treatment. Similarly, high expression of the prosurvival Bcl-2 family members (Bcl-2 and Bcl-xL) is frequent in advanced PCa and has been linked to drug resistance [23] . Therefore, targeting the expression of Bcl-2 family members, for example, Bcl-2, Bcl-xL, Bcl-W, and Mcl-1, could sensitize cells to chemotherapy [23] [24] [25] . The comprehensive drug testing identified several clinical and emerging drugs showing selective efficacy against the CRPC-derived HUB.5 CRCs (Fig. 3 ). Importantly, we were able to find efficacies for nonhormonal drugs such as taxanes, which are commonly used in clinical practice, as well as less well-established anti-PCa drugs such as mepacrine, oxaliplatin, and navitoclax, many of which are also currently undergoing clinical trials in different combinations for CRPC. Indeed, the drug sensitivity profile identified for HUB.5 CRCs-the CRPC culture established in this study-provides both validation of the efficacy of existing and emerging anti-PCa drugs as well as generates starting points for new drug repositioning efforts in CRPC. Thus, our approach to combine novel methods for culturing PCa primary cells with high-throughput drug testing technology provides insights for drug development, drug repositioning, and possibly in the future, precision oncology.
Conclusions
Better functional understanding of cell signaling and drug vulnerabilities in clinical human PCa tissues is urgently required to enable therapeutic discoveries. This study provides proof of concept for establishing CRCs from CRPC patients. Drug sensitivity testing of these CRPC-derived CRCs highlighted sensitivity to several potential oncology drugs such as taxanes, mepacrine, oxaliplatin, and navitoclax. The most potent effects were seen with navitoclax, which was linked to the overexpression of Bcl-2 family members and induction of apoptosis. 
